Alfresa Holdings Corporation (ARHCF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Alfresa Holdings Corporation · ARHCF
Alfresa Holdings Corporation is a Japanese healthcare company engaged in the wholesale, manufacture, and import/export of pharmaceuticals, diagnostic reagents, and medical devices. The company serves hospitals, clinics, dispensing pharmacies, and drug stores, operating across ethical pharmaceuticals, self-medication products, and medical-related businesses.
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| 52-week range | $11.87 – $14.59 | |
| Price / earnings (trailing) | 10.28 | — |
Price & events
Other perspectives
Council score for Alfresa Holdings (ARHCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ARHCF film — every key number, told as a short cinematic story
~2 min · open the film
What is Alfresa Holdings (ARHCF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Alfresa Holdings Corporation (ARHCF) is the company analyzed here. It employs 12,525 people and is led by Ryuji Arakawa. In Q1 FY2027 it reported revenue of $4.96B and net income of $16M.
What do the latest results show for Alfresa Holdings (ARHCF)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $4.96B. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $4.96B | $16M | $0.09 (diluted) |
| Q4 FY2026 | $4.72B | $62M | $0.34 (diluted) |
| Q3 FY2026 | $5.28B | $130M | $0.71 (diluted) |
| Q2 FY2026 | $4.95B | $42M | $0.23 (diluted) |
What are the financial strengths and risks for Alfresa Holdings (ARHCF)?
Short answer · as of
The distress and quality screens read Altman Z 2.96 · Piotroski F 6. Trailing ratios: ROE 7.9% · ROA 2.6% · current ratio 1.21 · earnings yield 9.7%.
Common Questions About ARHCF
These answers are editorial: 1 of these 1 answer is drawn from the ARHCF research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What does Alfresa Holdings Corporation do?
Alfresa Holdings Corporation is a multifaceted Japanese healthcare company primarily involved in the wholesale, manufacture, and import/export of a wide array of healthcare products.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (10 figures)
The 10 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 4 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.pe | Price / earnings (trailing) | 10.28 | — | FMP | Financial Modeling Prep (FMP) · quote |
fin.q_revenue | Revenue, Q1 FY2027 | $4.96B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q1 FY2027 | $16M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $11.87 – $14.59 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 12,525 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Ryuji Arakawa | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-01 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.96 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.9% · ROA 2.6% · current ratio 1.21 · earnings yield 9.7% | UNRECORDED | Stored key metrics — Captured 2026-10-01 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.